QCM
REGN icon

Qsemble Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Qsemble Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-851
Closed -$657K – 590
2025
Q4 		$657K Sell
851
-268
-24% -$182K 0.05% 339
2025
Q3 		$629K Sell
1,119
-9,349
-89% -$5.29M 0.06% 302
2025
Q2 		$5.5M Sell
10,468
-1,848
-15% -$1.03M 0.53% 60
2025
Q1 		$7.81M Buy
12,316
+7,548
+158% +$5.19M 0.83% 18
2024
Q4 		$3.4M Buy
+4,768
New +$4M 0.45% 73
2024
Q1 		– Sell
-239
Closed -$210K – 511
2023
Q4 		$210K Buy
+239
New +$197K 0.05% 328
2023
Q2 		– Sell
-1,020
Closed -$838K – 314
2023
Q1 		$838K Buy
+1,020
New +$769K 0.56% 60

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Qsemble Capital Management's REGN Position: Q1 2026 in Review

Qsemble Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 851 shares — an estimated $657K sold.

Qsemble Capital Management first reported a position in REGN in Q1 2023 and held it in 7 quarters. The position peaked at $7.81M in Q1 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Qsemble Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Qsemble Capital Management sold 851 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $657K.
  • Qsemble Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2023 and held it in 7 quarters.
  • Qsemble Capital Management's Regeneron Pharmaceuticals position peaked at $7.81M in Q1 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Qsemble Capital Management's 13F filing for Q1 2026, filed 7 May 2026.